Salvatore Cortellino

Dr. Salvatore Cortellino

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Cell
Verified
Journal Article
Closed access
SCSalvatore Cortellino
Salvatore Cortellino
JXJinfei Xu
Jinfei Xu
MSMara Sannai
Mara Sannai
RMRobert Moore
Robert Moore
ECElena Caretti
Elena Caretti
ABAlfonso Bellacosa
Alfonso Bellacosa

16 October 2018 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
ANAlessio Nencioni
Alessio Nencioni
ICIrene Caffa
Irene Caffa
SCSalvatore Cortellino
Salvatore Cortellino
VLValter Longo
Valter Longo

15 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
Irene CaffaIrene Caffa
Irene Caffa
VSVanessa Spagnolo
Vanessa Spagnolo
CVClaudio Vernieri
Claudio Vernieri
FVFrancesca Valdemarin
Francesca Valdemarin
PBPamela Becherini
Pamela Becherini
ANAlessio Nencioni
Alessio Nencioni

17 November 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CVClaudio Vernieri
Claudio Vernieri
GFGiovanni Fucà
Giovanni Fucà
FLFrancesca Ligorio
Francesca Ligorio
VHVeronica Huber
Veronica Huber
AVAndrea Vingiani
Andrea Vingiani
FBFilippo de Braud
Filippo de Braud
In tumor-bearing mice, cyclic fasting or fasting-mimicking diets (FMD) enhance the activity of antineoplastic treatments by modulating systemic metabolism and boosting antitumor immunity. Here we conducted a clinical trial to investigate the safety and biological effects of cyclic, five-day FMD in combination with standard antitumor therapies. In 101 patients, the FMD was safe, feasible, and resulted in a consistent decrease of blood glucose and growth factor concentration, thus recapitulating metabolic changes that mediate fasting/FMD anticancer effects in preclinical experiments. Integrated transcriptomic and deep-phenotyping analyses revealed that FMD profoundly reshapes anticancer immunity by inducing the contraction of peripheral blood immunosuppressive myeloid and regulatory T-cell compartments, paralleled by enhanced intratumor Th1/cytotoxic responses and an enrichment of IFNγ and other immune signatures associated with better clinical outcomes in patients with cancer. Our findings lay the foundations for phase II/III clinical trials aimed at investigating FMD antitumor efficacy in combination with standard antineoplastic treatments. Significance: Cyclic FMD is well tolerated and causes remarkable systemic metabolic changes in patients with different tumor types and treated with concomitant antitumor therapies. In addition, the FMD reshapes systemic and intratumor immunity, finally activating several antitumor immune programs. Phase II/III clinical trials are needed to investigate FMD antitumor activity/efficacy. This article is highlighted in the In This Issue feature, p. 1

27 September 2013 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
Andrea DisanzaAndrea Disanza
Andrea Disanza
SBSara Bisi
Sara Bisi
MWMoritz Winterhoff
Moritz Winterhoff
FMFrancesca Milanesi
Francesca Milanesi
DUDmitry S Ushakov
Dmitry S Ushakov
GSGiorgio Scita
Giorgio Scita
Filopodia explore the environment, sensing soluble and mechanical cues during directional motility and tissue morphogenesis. How filopodia are initiated and spatially restricted to specific sites on the plasma membrane is still unclear. Here, we show that the membrane deforming and curvature sensing IRSp53 (Insulin Receptor Substrate of 53 kDa) protein slows down actin filament barbed end growth. This inhibition is relieved by CDC42 and counteracted by VASP, which also binds to IRSp53. The VASP:IRSp53 interaction is regulated by activated CDC42 and promotes high‐density clustering of VASP, which is required for processive actin filament elongation. The interaction also mediates VASP recruitment to liposomes. In cells, IRSp53 and VASP accumulate at discrete foci at the leading edge, where filopodia are initiated. Genetic removal of IRSp53 impairs the formation of VASP foci, filopodia and chemotactic motility, while IRSp53 null mice display defective wound healing. Thus, IRSp53 dampens barbed end growth. CDC42 activation inhibits this activity and promotes IRSp53‐dependent recruitment and clustering of VASP to drive actin assembly. These events result in spatial restriction of VASP filament elongation for initiation of filopodia during cell migration, invasion, and tissue repair.

1 March 2003 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
MBMassimiliano Baldassarre
Massimiliano Baldassarre
APArsenio Pompeo
Arsenio Pompeo
GBGalina Beznoussenko
Galina Beznoussenko
CCClaudia Castaldi
Claudia Castaldi
SCSalvatore Cortellino
Salvatore Cortellino
RBRoberto Buccione
Roberto Buccione
The degradation of extracellular matrix (ECM) by matrix metalloproteases is crucial in physiological and pathological cell invasion alike. Degradation occurs at specific sites where invasive cells make contact with the ECM via specialized plasma membrane protrusions termed invadopodia. Herein, we show that the dynamin 2 (Dyn2), a GTPase implicated in the control of actin-driven cytoskeletal remodeling events and membrane transport, is necessary for focalized matrix degradation at invadopodia. Dynamin was inhibited by using two approaches: 1) expression of dominant negative GTPase-impaired or proline-rich domain-deleted Dyn2 mutants; and 2) inhibition of the dynamin regulator calcineurin by cyclosporin A. In both cases, the number and extension of ECM degradation foci were drastically reduced. To understand the site and mechanism of dynamin action, the cellular structures devoted to ECM degradation were analyzed by correlative confocal light-electron microscopy. Invadopodia were found to be organized into a previously undescribed ECM-degradation structure consisting of a large invagination of the ventral plasma membrane surface in close spatial relationship with the Golgi complex. Dyn2 seemed to be concentrated at invadopodia.